verinurad + allopurinol + cyclosporine

A **combination of verinurad, allopurinol, and cyclosporine** administered orally as single doses in clinical studies to assess pharmacokinetics and drug-drug interactions in healthy subjects. - **Verinurad** is a selective urate transporter 1 (URAT1) inhibitor with uricosuric activity, lowering serum uric acid by inhibiting reabsorption in the kidneys. - **Allopurinol** is a xanthine oxidase inhibitor that reduces urate production by blocking the conversion of xanthine to uric acid. - **Cyclosporine** is a calcineurin inhibitor primarily used as an immunosuppressive agent but can affect renal handling and drug metabolism. The combination was studied (Phase 1) for its pharmacokinetic interactions and safety profile in healthy volunteers, particularly in the context of chronic kidney disease and possible drug interactions[3]. No evidence of clinical use or efficacy for disease treatment as a combination outside of research settings.